Peer vitiligo data validates TRAX IL-15/CD122 pathway for sympathy surge
- Forte Biosciences (FBRX) reported positive Phase 1b vitiligo data for FB102 on July 9, 2026
- FB102 modulates IL-2/IL-15 pathways; TRAX's ANB033 is CD122 (IL-15R beta) antagonist also in vitiligo trials
- Pathway validation triggered retail and institutional buying in TRAX as sympathy play
- TRAX shares surged ~26-30% intraday with elevated volume; hit highs near $28
- Analysts previously flagged ANB033 vitiligo data as key upcoming catalyst (Q4 2026 celiac data also pending)
- HC Wainwright reiterated Buy/$30 PT around same time, adding support
- TRAX, spun from AnaptysBio in Apr 2026, holds ~$180M cash for multiple Phase 1b/2 programs
- No direct TRAX news; move purely tied to peer validation in shared autoimmune space
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.